Sen. Bill Cassidy (R-La.) on Tuesday night pushed back against the White House's decision to withdraw Heidi Overton as its nominee to lead the Food and Drug Administration, saying he believed she had enough support to be confirmed and that the administration's stated reason did not add up.

"Tonight, the White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members," Cassidy wrote on X. "I believe she would have had the votes to pass out of committee and pass the full Senate."

Read also
Politics
Johnson walks back Social Security 'Ponzi scheme' shutdown remark
Sen. Ron Johnson (R-Wis.) said there's 'no way to fix' Social Security and called it a 'Ponzi scheme,' but later said his remarks were 'imprecise.' Democrats slammed the idea of shutting down the program.

Cassidy, a physician who chairs the Senate health committee, has been a frequent critic of President Trump's health nominees, though he has ultimately voted to support them. He had initially raised concerns about Overton's backing of Trump's push to alter the childhood vaccine schedule, but said he changed his mind after she assured him she would "follow the science" at the FDA.

"My conversations with her convinced me she would follow the science and push back against decisions that put Americans' health at risk," Cassidy said. "Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats."

Democrats are poised to take a sizable majority in the Senate next year, which would complicate any future Trump nominee for the FDA post. The White House confirmed to The Hill that it withdrew Overton's nomination on Tuesday evening, just before a scheduled committee vote.

Overton, a prominent health adviser in Trump's orbit who leads the White House Domestic Policy Council, has been a vocal supporter of Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again movement and has taken a strong anti-abortion stance. She drew criticism during her confirmation hearings for refusing to say whether Trump was wrong about past vaccine safety claims.

Cassidy said the final sticking point was not Overton herself but the administration's unwillingness to make firm commitments on abortion-related policies. "The last issue was that pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues," he wrote. "The Administration withdrew Dr. Overton rather than make such commitments."

The withdrawal marks a significant setback for Trump's health agenda, as Overton had been seen as a key ally of Kennedy's efforts to overhaul federal health agencies. The move also highlights the delicate balance the White House faces in navigating Senate confirmations with a narrow Republican majority and a looming Democratic takeover.

Senate Democrats are expected to use the FDA vacancy as a rallying point in the next Congress, potentially slowing or blocking any interim appointments. The episode is likely to intensify scrutiny on the administration's handling of health nominations, particularly as it prepares to confront a new political landscape in Washington.

Cassidy's public criticism underscores the tension between the administration and key Senate Republicans over the direction of health policy, a rift that could have lasting implications for Trump's second-term agenda.